As part of its capital markets day, Grifols (GRFS) announced a five-year plan through 2029 which forecasts revenue of EUR 10B, EBITDA at EUR 2.9B, and cumulative free cash flow of EUR 3.5B-plus, with the company’s Biopharma business “leading growth across all business units.” The company’s “long-term value creation aims to double the business in the next decade, building on momentum of record performances in 2023 and 2024.” Grifols said it will focus on “accelerating the execution of its strategic plan, stressing financial discipline, operational excellence, innovation, cash flow improvement and deleveraging.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols SA Reports Record 2024 Financial Results
- Grifols reports Q4 adjusted EBITDA of EUR 526M, up 19% from last year
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Grifols price target lowered to EUR 15.25 from EUR 15.40 at Berenberg
- Grifols resumed with an Overweight at Morgan Stanley